Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.52 |
| ▸ | MMP13 | P45452 | 12/20 | 0.52 |
| ▸ | MMP1 | P03956 | 11/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7418731 | 0.87 | MMP9 (0.60) | MMP9MMP13MMP1LMNANR3C1 | |
| Hydroxyamine SCHEMBL8521982 | 0.81 | MMP9 (0.60) | MMP9MMP13MMP1LMNANR3C1 | |
| SCHEMBL6558860 | 0.81 | MMP9 (0.62) | MMP9MMP13MMP1LMNANR3C1 | |
| SCHEMBL7417553 | 0.79 | MMP9 (0.56) | MMP9MMP13MMP1LMNANR3C1 | |
| SCHEMBL8521983 | 0.78 | MMP9 (0.58) | MMP9MMP13MMP1LMNANR3C1 | |
| SCHEMBL7453152 | 0.78 | MMP9 (0.62) | MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6559690 | 0.77 | MMP9 (0.63) | MMP9MMP13MMP1LMNANR3C1 | |
| SCHEMBL7467779 | 0.76 | MMP9 (0.78) | MMP9MMP13MMP1ADAM17 | |
| SCHEMBL7322409 | 0.76 | MMP9 (0.66) | MMP9MMP13MMP1LMNANR3C1 | |
| SCHEMBL7463546 | 0.75 | MMP9 (0.59) | MMP9MMP13MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934300-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-12-18 | — | — | EP | claimed |
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | LEVIN JEREMY IAN (US) | 2001-12-13 | — | — | US | claimed |
| US-6162814-A | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2000-12-19 | — | — | US | claimed |
| EP-0934300-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1998016520-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0934300-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | LEVIN JEREMY IAN (US) | 2001-12-13 | — | — | US | disclosed |
| US-6197795-B1 | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; WOUND HEALING AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6162814-A | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| US-6162821-A | Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-19 | — | — | US | disclosed |
| US-5962481-A | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; WOUND HEALING AGENTS;ANTIULCER AGENTS; ORAL DISEASES; CENTRAL NERVOUS SYTEM DISORDERS; ANTIINFLAMMATORY AGENTS; CONGESTIVE HEART FAILURE;VISION DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MMP1, MMP12, MMP26 | MMP9 10/4885MMP13 8/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.